Infinity Clinical Research

1. Eli Lilly and Company $1,255,547 21 payments
2. Biogen, Inc. $202,198 3 payments
3. Welch Allyn $102,089 12 payments
4. Ipsen Innovation $94,760 95 payments
5. Novartis Pharmaceuticals Corporation $58,453 6 payments
6. Anika Therapeutics, Inc. $57,614 19 payments
7. AstraZeneca Pharmaceuticals LP $53,141 4 payments
8. Sun Pharmaceutical Industries Inc. $50,563 5 payments
9. Vertex Pharmaceuticals Incorporated $30,371 1 payment
10. Organogenesis Inc. $24,013 3 payments

1. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-3) $797,916 4 payments
2. A Study of Orforglipron (Ly3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (Achieve-1) $289,311 4 payments
3. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $200,889 1 payment
4. AutoDx-DR Prospective Clinical Validation Study Protocol $102,089 12 payments
5. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $68,581 2 payments
6. RXLC 2118 $59,563 6 payments
7. A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee $57,614 19 payments
8. A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $56,993 57 payments
9. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $37,767 38 payments
10. A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects with Pain Caused by Small Fiber Neuropathy $30,371 1 payment

1. Other $102,089 12 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.